Catalyst Pharmaceuticals, Inc. $CPRX Position Raised by Systematic Financial Management LP

Posted by Brian Himes on May 24th, 2026

Systematic Financial Management LP raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 5.5% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 723,242 shares of the biopharmaceutical company’s stock after buying an additional 37,578 shares during the quarter. Systematic Financial Management LP owned approximately 0.59% of Catalyst Pharmaceuticals worth $16,880,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in CPRX. Deerfield Management Company L.P. lifted its stake in Catalyst Pharmaceuticals by 72.8% in the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after buying an additional 2,095,291 shares during the last quarter. American Century Companies Inc. lifted its stake in Catalyst Pharmaceuticals by 43.8% in the third quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock valued at $49,805,000 after buying an additional 770,198 shares during the last quarter. Fundsmith LLP lifted its stake in Catalyst Pharmaceuticals by 24.2% in the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock valued at $66,267,000 after buying an additional 654,721 shares during the last quarter. Glenmede Investment Management LP lifted its stake in Catalyst Pharmaceuticals by 781.8% in the third quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock valued at $13,400,000 after buying an additional 603,084 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in Catalyst Pharmaceuticals by 30.6% in the second quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock valued at $51,335,000 after buying an additional 554,200 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Stock Down 0.1%

Shares of NASDAQ CPRX opened at $31.26 on Friday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The firm’s 50-day simple moving average is $26.81 and its 200 day simple moving average is $24.68. The stock has a market cap of $3.83 billion, a P/E ratio of 17.97, a P/E/G ratio of 0.91 and a beta of 0.72.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Weiss Ratings restated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Friday, March 27th. Oppenheimer cut shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. Citigroup cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $35.00 to $31.50 in a research note on Friday, May 8th. Zacks Research cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.17.

View Our Latest Research Report on CPRX

Catalyst Pharmaceuticals Profile

(Free Report)

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).